Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCTIC phase III trial in previously treated advanced non-small cell lung cancer
NL-OMON45219Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45219.